Abstract
Accumulation of the amyloid β-peptide (Aβ) in the brain is believed to initiate a series of neurotoxic events that causes neurodegeneration in Alzheimer´s disease (AD). Aβ is generated by processing of the β-amyloid precursor protein (APP) through the successive action of two proteolytic enzymes, β-secretase and γ-secretase. While β-secretase has been identified as the membrane-bound aspartyl protease BACE, the identity of γ-secretase, which catalyzes the final, intramembrane cleavage of APP as well as of several other type I transmembrane proteins, has been enigmatic for a long time. Exciting progress has been made in the past year towards its uncovering. Genetics paved the way for subsequent biochemical reconstitution studies that demonstrated that γ-secretase is a protein complex composed of presenilin (PS), nicastrin (NCT), APH-1 and PEN-2. Thus, the complete set of genes that is required to generate Aβ from its precursor has now ultimately been identified. PS carries the active site of γ-secretase and is a founding member of a novel class of polytopic aspartyl proteases that utilize a non-classical active site to cleave their membrane-tethered substrates. The other components are required for assembly, stabilization and maturation of the complex and NCT may be involved in the recognition of γ-secretase substrates.
Keywords: alzheimer's disease, amyloid peptide, aph-1, nicastrin, pen-2, presenilin, secretase, secretase complex
Current Alzheimer Research
Title: Uncovering γ-Secretase
Volume: 1 Issue: 3
Author(s): Harald Steiner
Affiliation:
Keywords: alzheimer's disease, amyloid peptide, aph-1, nicastrin, pen-2, presenilin, secretase, secretase complex
Abstract: Accumulation of the amyloid β-peptide (Aβ) in the brain is believed to initiate a series of neurotoxic events that causes neurodegeneration in Alzheimer´s disease (AD). Aβ is generated by processing of the β-amyloid precursor protein (APP) through the successive action of two proteolytic enzymes, β-secretase and γ-secretase. While β-secretase has been identified as the membrane-bound aspartyl protease BACE, the identity of γ-secretase, which catalyzes the final, intramembrane cleavage of APP as well as of several other type I transmembrane proteins, has been enigmatic for a long time. Exciting progress has been made in the past year towards its uncovering. Genetics paved the way for subsequent biochemical reconstitution studies that demonstrated that γ-secretase is a protein complex composed of presenilin (PS), nicastrin (NCT), APH-1 and PEN-2. Thus, the complete set of genes that is required to generate Aβ from its precursor has now ultimately been identified. PS carries the active site of γ-secretase and is a founding member of a novel class of polytopic aspartyl proteases that utilize a non-classical active site to cleave their membrane-tethered substrates. The other components are required for assembly, stabilization and maturation of the complex and NCT may be involved in the recognition of γ-secretase substrates.
Export Options
About this article
Cite this article as:
Steiner Harald, Uncovering γ-Secretase, Current Alzheimer Research 2004; 1 (3) . https://dx.doi.org/10.2174/1567205043332081
DOI https://dx.doi.org/10.2174/1567205043332081 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Voltammetric Sensing of Uremic Toxin Indoxyl Sulfate Using High Performance Disposable Screen-Printed Graphene Electrode
Current Pharmaceutical Analysis Ethosomes as Novel Vesicular Carrier: An Overview of the Principle, Preparation and its Applications
Current Drug Delivery Early Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?
Current Pharmaceutical Design Nonviral Approach for Targeted Nucleic Acid Delivery
Current Medicinal Chemistry Reliability of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) in longitudinal Studies
Current Alzheimer Research Meet Our Executive Editor
Current Traditional Medicine Melatonin Effects on Plasmodium Life Cycle: New Avenues for Therapeutic Approach
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Is Cdc25 a Druggable Target?
Anti-Cancer Agents in Medicinal Chemistry Precipitation of Uniform ZnO Particles with Controllable Layered Structure from Aqueous Solutions
Current Nanoscience Concept of Comprehensive Treatment for Osteoarthritis (OA)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Child Mental Health in the Philippines
Adolescent Psychiatry Nanofillers for Food Packaging: Antimicrobial Potential of Metal-based Nanoparticles
Current Nanotoxicity and Prevention (Discontinued) Editorial (Thematic Issues: Basic and Clinical Aspects of Melatonin in the Gastrointestinal Tract. New Advancements and Future Perspectives)
Current Pharmaceutical Design Applications of LC-MS in PET Radioligand Development and Metabolic Elucidation
Current Drug Metabolism Prenatal Diagnosis Preferences of Turkish Women and the Association of their Choices with Temperament
Current Women`s Health Reviews Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents Meet Our Editorial Board Member:
Current Alzheimer Research